

PRESS RELEASE

Gradientech announces outcome of rights issue

Uppsala, Sweden, March 26, 2026. **The diagnostics company Gradientech AB (publ) ("Gradientech" or the "Company") today announces the outcome of the new issue of shares with preferential rights for existing shareholders (the "Rights Issue") resolved by the Board of Directors on February 26, 2026. The final count in the Rights Issue shows that 5,619,127 shares, corresponding to approximately 87 percent of the Rights Issue, were subscribed for with and without the support of subscription rights. Through the Rights Issue, Gradientech will receive approximately SEK 49.2 million before deductions for issue costs, of which SEK 14 million will be used to offset loans.**

The subscription period for the Rights Issue expired on March 23, 2026. The final outcome shows that 2,493,786 shares, corresponding to approximately 44 percent of the Rights Issue, were subscribed for with subscription rights and 3,125,341 shares, corresponding to approximately 56 percent of the Rights Issue, without subscription rights. Through the Rights Issue, the Company's share capital will increase by SEK 561,912.70 to SEK 3,795,035.90 and the number of shares will increase by 5,619,127 shares to 37,950,359 shares.

Approximately one week after the Rights Issue has been registered with the Swedish Companies Registration Office, which is expected to take place in April 2026, BTA will be converted into shares. Allotment of shares subscribed for without subscription rights has been made in accordance with the principles set out in the prospectus prepared in connection with the Rights Issue and published by the Company on March 4, 2026. Notification of allotment will be made by means of a settlement note to each subscriber. Allocated shares shall be paid in accordance with the instructions on the settlement note.

No compensation is paid for submitted subscription commitments. Aqurat Fondkommission AB is acting as issuing agent and Advokatfirman Lindahl KB is acting as legal advisor to Gradientech in connection with the issue.

For further information, please contact:

Sara Thorslund, PhD, CEO
Phone: +46 (0)736 29 35 80
sara.thorslund@gradientech.se

Urban Adolfsson, CFO
Phone: + 46 708 20 72 09
urban.adolfsson@gradientech.se

About Gradientech

Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance - one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit [gradientech.se](https://www.gradientech.se) for more information.

